Table 2 Expression of SF-25 antigen on peripheral blood lymphocytes from patients with adult T-cell leukemia/lymphoma and human T-cell leukemia virus type I healthy carriers.

From: Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma

Subtype

Positive/total

Positive rate (%)

Acute ATL

11/11

100

Chronic ATL

5/5

100

Smoldering ATL

12/12

100

HTLV-1 healthy carriers

2/52

3.8

  HTLV-1 clonal integration ( −)

0/45

0

  HTLV-1 oligoclonal integration ( +)

2*/7

28.6

Healthy control (non-HTLV-1 carrier)

0/8

0

  1. Cut off point: SF-25-Ag positive as the 1.7% according to the mean+2SD of expression in HTLV-1 healthy carriers.
  2. ATL adult T-cell leukemia/lymphoma; HTLV-1 human T-cell leukemia virus type I.
  3. *Two HTLV-1 healthy carriers with oligoclonal integration showed SF-25 positive cells as 1.9% and 2.3%.
Back to article page